Flashlight

DOI: 10.4244/EIJ-D-24-00871

Management of bioprosthetic valve failure at 10 years after TAV-in-SAV

Julius Jelisejevas1,2, MD; John G. Webb-1,3, MD; David A. Wood1,2, MD

Structural deterioration of bioprosthetic heart valves, manifesting as stenosis and/or regurgitation, remains the primary factor limiting valve longevity. As patients undergoing valve replacement have increasingly longer life expectancies, planning lifelong management is essential1. This trend also highlights the need to balance surgical and transcatheter options in redo procedures, which is an evolving conversation in which transcatheter options may offer a less invasive alternative to surgery2. Here, we report a challenging case in the lifelong management of aortic valve disease of a 66-year-old female with significant comorbidities, including chronic kidney disease, end-stage liver disease, and a complex cardiac history.

The patient was initially treated at the age of 47 due to native aortic valve endocarditis, necessitating surgical aortic valve replacement (SAVR) with a 21 mm Carpentier-Edwards PERIMOUNT (Edwards Lifesciences). The procedure involved root enlargement and congenital ventricular septal defect repair, complicated by coagulopathy, leading to a prolonged hospital stay but a favourable overall outcome. Nine years later, at age 56, she underwent a transcatheter aortic valve-in-surgical aortic valve (TAV-in-SAV) procedure, owing to the risk of coronary obstruction and sinus sequestration...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 8
Apr 21, 2025
Volume 21 Number 8
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV9SSA15 Sep 15, 2013
Failing surgical bioprosthesis in aortic and mitral position
Mylotte D et al
free

State-of-the-Art Review

10.4244/EIJ-D-21-00157 Oct 20, 2021
Transcatheter aortic valve implantation in degenerated surgical aortic valves
Tarantini G et al
free

EXPERT REVIEW

10.4244/EIJ-D-18-00667 Sep 7, 2018
Novel strategies in aortic valve-in-valve therapy including bioprosthetic valve fracture and BASILICA
Dvir D et al
free

10.4244/EIJV11SWA34 Sep 17, 2015
Durability of devices: long-term results and clinical outcomes
Arsalan M and Mack MJ
free

10.4244/EIJV14I2A24 Jun 20, 2018
Transcatheter aortic valve implantation: don’t forget the coronary arteries!
Søndergaard L and De Backer O
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved